Stock News & Analysis

Sunrun delivers residential solar and battery storage solutions to U.S. homeowners through a direct-to-consumer model.

This aluminum producer has been flourishing, and with the metal's price soaring, the company continues to benefit.

Alibaba's e-commerce empire may no longer be the company's biggest growth story. Instead, artificial intelligence and cloud infrastructure are quickly taking center stage.

This clinical-stage biotech develops oncology therapies targeting unmet needs in cancer and immune-mediated conditions.

AI stocks have had a bad 2026 so far.

After a rough Q4 FY 2025 earnings, Ralliant's stock has reached an all-time low. Yet, one of the company's board directors purchased insider shares after the underwhelming earnings.

This healthcare firm develops advanced surgical solutions for peripheral nerve repair, serving hospitals and specialists worldwide.

This global beverage company had a strong run in 2025, and now, its stock is set to join one of the top funds in the market.

Biohaven develops clinical-stage therapies for neurological and immunoscience disorders, with no commercialized products to date.

This biotech firm develops therapies for rare, complement-driven diseases, with a focus on autoimmune and inflammatory conditions.

There's good news and bad news for investors right now.

Cogent Biosciences develops targeted therapies for genetically defined diseases, focusing on precision medicine for rare cancers.

The world's largest publisher of children's books is buying back a large swath of its shares.

This China-based tech firm links employers and job seekers through its digital recruitment platform serving a broad labor market.

Tesla will face new competition next month.

After an impressive 953% trailing-10-year total return, investors are ready to tackle the next milestone.

Micron is experiencing similar sharp revenue growth to Nvidia during the early months following the launch of ChatGPT.

Social media companies other than Meta Platforms are struggling to gain investor traction.

This clinical-stage biotech develops oral therapies targeting cancer and inflammatory diseases, with lead candidates in active trials.

This financial technology stock is struggling to shift investor sentiment.